Home › Opioid Overdose › NCT06521476

Acetazolamide in Central Sleep Apnea Patients Using Medication for Opioid Use Disorder

Impact of Acetazolamide on Central Sleep Apnea Patients Receiving Medication for Opioid Use Disorder

Who can join

Ages 18 to 100 · All sexes

Inclusion Criteria:

* Patients on Medication for Opioid Use Disorder (MOUD) with central sleep apnea.

Exclusion Criteria:

* Sleep-related Hypoventilation.
* Other causes of Central Sleep Apnea besides Opioid Use.
* Pregnancy.
* Contraindications for Acetazolamide.

About the study

Patients with opioid use disorder treated with either methadone or buprenorphine are at risk of developing central sleep apnea (CSA) from these medications. Investigators will conduct a mechanistic trial using acetazolamide, a medicine known to improve CSA in other settings, to determine if acetazolamide can improve CSA due to medication for opioid use disorder and whether this leads to physiologic changes that might lead to reduced drug craving. Patients treated with medication for opioid use disorder and who have central sleep apnea will be randomized to treatment with acetazolamide or matching placebo for 7 days. At the end of the 7 days, they will undergo an overnight sleep study to assess the impact on breathing during sleep as well as sleep quality. In addition, measures of sympathetic tone, anxiety, arousal, cognition, and drug craving will be measured to determine if treatment of CSA with acetazolamide can produce physiologic changes that might contribute to improved health.

What is being tested

• Acetazolamide (drug)
• Placebo (drug)

Sponsor: Sanjay R Patel · Participants: 40 · Started: Sep 30, 2025

Contact the study team

• Madeline Gudobba · Phone: 412-648-9507
• Stormy Green · Phone: 412-383-9469

Official record on ClinicalTrials.gov — NCT06521476

Locations in the U.S.

Conditions

• Opioid Overdose

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.